Cargando…

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

BACKGROUND: Comparative effectiveness (CE) research allows real-world treatment comparisons using outcome measurements important to physicians/patients. This German NeuroTransData registry-based analysis compared delayed-release dimethyl fumarate (DMF) effectiveness with interferons (IFN), glatirame...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braune, Stefan, Grimm, Sarah, van Hövell, Philip, Freudensprung, Ulrich, Pellegrini, Fabio, Hyde, Robert, Bergmann, Arnfin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244642/ https://www.ncbi.nlm.nih.gov/pubmed/30327931 http://dx.doi.org/10.1007/s00415-018-9083-5

Ejemplares similares

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry
por: Wehrle, Knut, et al.
Publicado: (2022)

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData
por: Bergmann, Arnfin
Publicado: (2020)

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry
por: Braune, Stefan, et al.
Publicado: (2023)

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry
por: Jiang, Xiaotong, et al.
Publicado: (2023)

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
por: Braune, Stefan, et al.
Publicado: (2022)

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
por: Braune, Stefan, et al.
Publicado: (2021)

The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients
por: Dabbaghi, Rozhin, et al.
Publicado: (2023)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity
por: Maghazachi, Azzam A., et al.
Publicado: (2016)

The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry
por: Dillon, Paul, et al.
Publicado: (2023)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs
por: Derakhshani, Afshin, et al.
Publicado: (2021)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
por: Kemmerer, C. L., et al.
Publicado: (2020)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis
por: Groh, Janos, et al.
Publicado: (2017)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1llgo83re0hk61spv1prq4t5o